Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry-Reference-Cited by-同舟云学术

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry

Published:2014-09-19 Issue:4 Volume:78 Page:908-917
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Beyer-Westendorf Jan¹,Gelbricht Vera¹,Förster Kati¹,Ebertz Franziska¹,Röllig Denise¹,Schreier Thomas¹,Tittl Luise¹,Thieme Christoph¹,Hänsel Ulrike¹,Köhler Christina¹,Werth Sebastian¹,Kuhlisch Eberhard²,Stange Thoralf²,Röder Ingolf²,Weiss Norbert¹

Affiliation:

1. Center for Vascular Medicine and Department of Medicine III; Division of Angiology; University Hospital Carl Gustav Carus at the Technische Universität Dresden; Fetscherstrasse 74 01307 Dresden Germany

2. Institute for Medical Informatics and Biometry; Technische Universität Dresden; Dresden Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12391/fullpdf

Reference13 articles.

1. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

2. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

3. Oral rivaroxaban for symptomatic venous thromboembolism;Bauersachs;N Engl J Med,2010

4. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines;Weitz;Chest,2012

5. SmPC rivaroxaban http://wwwmedicinesorguk/emc/medicine/25586/SPC

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea;Advances in Therapy;2022-05-07

2. Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY;Thrombosis Research;2021-12

3. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry;Thrombosis Research;2021-06

4. Rational and design of the China Pulmonary Thromboembolism Registry Study (CURES): A prospective multicenter registry;International Journal of Cardiology;2020-10

5. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation;American Journal of Epidemiology;2020-07-08